# VERTEX PHARMACEUTICALS INC / MA stock analysis

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF

## Market evidence and data freshness

The public preview recorded VERTEX PHARMACEUTICALS INC / MA at 545.07 USD on 2026-11-05T20:02:10.000Z and marked the quote as delayed. This observation is not a trading signal.
Available price history spans 2026-05-11 through 2026-11-04 across 118 observations; the listed source is CommonQuant Parquet archive backed by Yahoo Finance delayed data. The history end date differs from the latest quote date.

## Published research mentioning VRTX

These are separate dated research reports, not a consensus view or a current signal.

- [Vertex drops $10B to dominate hormone treatments — ride the acquisition momentum](https://commonquant.ai/research/for-you/vertex-drops-10b-to-dominate-hormone-treatments-ride-the-acq--188a0ecf-877f-4378-93b9-483d002a9613) — 2026-09-08 UTC

## What should I review before buying VERTEX PHARMACEUTICALS INC / MA stock?

Compare valuation with reported financial performance, inspect the price history, and weigh the evidence for and against the investment case. Review the risks and assumptions before making your own decision.

## Inside the full report

- Valuation
- Growth
- Financial health
- Ownership
- Research

Sign in to open the full analysis. Paid plans use included reports first, then your weekly usage limit. Access lasts 72 hours, including revisits.

[Read the report](https://commonquant.ai/markets/vrtx)